

#### **UK Office**

#### **Everest Biotech Ltd**

Cherwell Innovation Centre 77 Heyford Park Upper Heyford Oxfordshire OX25 5HD UK

**Enquiries:** 

info@everestbiotech.com

Sales:

sales@everestbiotech.com

Tech support:

support@everestbiotech.com

Tel: +44 (0)1869 238326

www.everestbiotech.com

Research Use Only. Not for diagnostic or therapeutic use.

# EB06401 - Goat Anti-CYLD (C terminus) Antibody

Size: 100µg specific antibody in 200µl



## **Target Protein**

**Principal Names:** CYLD, EAC, CDMT, CYLD1, CYLDI, FLJ31664, FLJ78684, HSPC057, KIAA0849, USPL2, deubiquitinating enzyme CYLD, ubiquitin carboxyl-terminal hydrolase CYLD, ubiquitin specific peptidase like 2, ubiquitin thiolesterase CYLD, ubiquitin-specific-processing protease CYLD, cylindromatosis (turban tumor syndrome),

MFT, MFT1, SBS, TEM
Official Symbol: CYLD

Accession Number(s): NP\_056062.1; NP\_001035814.1; NP\_001035877.1

Human GeneID(s): 1540

Important Comments: This antibody is expected to recognize both reported isoforms

(NP\_056062.1 and NP\_001035814.1; NP\_001035877.1).

### **Immunogen**

Peptide with sequence CMYQSPTMSLYK, from the C Terminus of the protein sequence according to NP\_056062.1; NP\_001035814.1; NP\_001035877.1.

## **Purification and Storage**

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

Aliquot and store at -20°C. Minimize freezing and thawing.

## **Applications Tested**

Peptide ELISA: antibody detection limit dilution 1:16000.

**Western blot:** Preliminary experiments gave no signal but low background in human kidney and Hela lysates at up to 1µg/ml. We would appreciate any feedback from people in the field - have any results been reported with other antibodies/lysates?

## **Species Reactivity**

Tested:

Expected from sequence similarity: Human, Mouse, Rat, Dog, Cow

## **Background Reference**

Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, Toftgard R, Huber M.

The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.

J Exp Med. 2003 Dec 15;198(12):1959-64.

PMID: 14676304